Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions Inc.'s Chief Financial Officer Troy Wichterman reported a routine tax-related share withholding tied to restricted stock vesting. On this Form 4, 3,749 shares of Common Stock were withheld at $19.12 per share to satisfy tax obligations that arose when restricted stock units were released.
These shares were not sold in the open market; they were retained by the company to cover taxes. After this transaction, Wichterman holds 216,900 shares of BioLife Solutions common stock directly, indicating he retains a substantial equity position following the RSU vesting event.
BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 931 shares of common stock to cover her tax obligations at $19.12 per share. After this withholding, she directly owns 92,429 shares. This was not an open-market sale but a standard mechanism tied to equity compensation vesting.
BioLife Solutions executive Karen A. Foster had shares withheld to cover taxes on equity compensation. On the release of restricted stock units, the company withheld 1,907 shares of Common Stock at a value of $19.12 per share to satisfy her tax obligations. After this tax-withholding disposition, she holds 111,335 shares of BioLife Solutions Common Stock directly.
BioLife Solutions EVP & Chief Scientific Officer Mathew Aby J. reported a routine tax-related share disposition. On the release of restricted stock units, 2,255 shares of common stock were withheld by the company at $19.12 per share to cover his tax obligations. After this withholding, he continues to directly own 390,682 shares of BioLife Solutions common stock, indicating that only a small portion of his overall holdings was affected and that this was not an open-market sale.
BLFS affiliate filed a Form 144 reporting the proposed sale of 2,577 shares of Common Stock via exercise of stock options. The filing also lists recent 10b5-1 cash sales by Karen Foster on 03/05/2026 (96,923 shares), 03/09/2026 (500 shares), 03/03/2026 (418 shares), and 01/06/2026 (335 shares) with proceeds shown alongside each trade.
BioLife Solutions Chief Quality and Operations officer Karen A. Foster reported open-market sales of a total of 97,423 shares of common stock in two transactions, at weighted average prices of $20.15 and $20.00 per share across multiple trades. After these sales, she directly owns 113,242 shares.
BioLife Solutions, Inc. (BLFS) filed a Form 144 reporting a transaction involving 500 common shares on 03/09/2026 tied to the exercise of stock options and settled for cash. The filing also lists recent 10b5-1 sales: 96,923 shares on 03/05/2026 for $1,953,163.22, 418 shares on 03/03/2026 for $8,669.32, and 335 shares on 01/06/2026 for $8,572.65.
BioLife Solutions Inc. reported that Chief Technology Officer Sean Werner executed an open-market sale of 111 shares of common stock on March 3, 2026 at $20.74 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan.
According to the filing, the trading plan, effective February 24, 2022, was established to satisfy tax withholding obligations arising from the vesting of restricted stock. After this sale, Werner directly holds 49,932 shares of BioLife Solutions common stock.
BioLife Solutions Inc. executive Karen A. Foster, Chief Quality and Operations, sold 418 shares of common stock in an open-market transaction at $20.74 per share. After this sale, she directly owned 210,665 shares. The sale was executed under a pre-established Rule 10b5-1(c) trading plan adopted to cover tax withholding tied to the vesting of restricted stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, sold 529 shares of common stock at $20.74 per share in an open‑market transaction. The sale was made under a Rule 10b5-1(c) trading plan adopted effective 02-24-2022 to cover tax withholding from vested restricted stock. After this sale, he directly held 392,937 common shares.